Drug Discovery
Asia Leaders
Daphne Koller’s $800 Million AI Bet Is Reaching Its First Human Trial Test
Daphne Koller has financed insitro with roughly $800 million in capital and collaboration revenue. Its first AI-discovered MASH programme is nearing the point where patients, not models, set the valuation.
Asia Leaders
Demis Hassabis Raised $2.1 Billion to Industrialise AI Drug Design. The Clinic Has Yet to Validate the Engine
Demis Hassabis has given Isomorphic Labs the capital and computing ambition of a technology platform. The harder test is whether its drug candidates can survive the slower economics of human biology.
Asia Leaders
Daphne Koller Is Turning Insitro’s AI Platform Into Drug Candidates. Biology Still Sets the Clock
Daphne Koller has spent years building a machine-learning company around human biology. In 2026, insitro’s partnerships and preclinical programmes are beginning to test whether its data advantage can produce medicines rather than promising hypotheses.
Asia Leaders
Ardem Patapoutian Found Pressure Sensors Across the Body. Drugmakers Must Decide Where Not to Intervene
Ardem Patapoutian’s PIEZO discoveries are expanding into common diseases with large Asian markets. Commercial value will depend on tissue-specific control, not the breadth of possible indications.